THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND ISSUE NEW SHARES AND PROPOSED PAYMENT OF FINAL DIVIDEND AND PROPOSED RE-APPOINTMENT OF INDEPENDENT AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the annual general meeting of China Resources Medical Holdings Company Limited (華潤醫療控股有限公司) to be held at 14/F, Kunlun Center Office Building, No. 9, Fuyi Street, Fengtai District, Beijing, the People's Republic of China on Thursday, June 25, 2026 at 10 a.m. is set out on pages 21 to 25 of this circular. A form of proxy for use at the annual general meeting is also enclosed. Such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.crmedical.hk).

Whether or not you are able to attend the annual general meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the annual general meeting (i.e. not later than 10 a.m. Tuesday, June 23, 2026 (Hong Kong time)) or any adjournment thereof. Completion and delivery of the form of proxy will not preclude a shareholder from attending and voting in person at the annual general meeting should you so wish and, in such event, the form of proxy shall be deemed to be revoked.

June 3, 2026

CONTENTS

Page

Definitions 1

Letter from the Board 3

1. Introduction 4
2. Proposed Re-election of Retiring Directors 4
3. Proposed Granting of General Mandate to Repurchase Shares 5
4. Proposed Granting of General Mandate to Issue New Shares 5
5. Proposed Payment of Final Dividend 5
6. Proposed Re-appointment of Independent Auditor 7
7. Annual General Meeting and Proxy Arrangement 8
8. Recommendation 8
9. Responsibility Statement 8

Appendix I — Details of the Retiring Directors Proposed to be Re-elected at the Annual General Meeting 9

Appendix II — Explanatory Statement on the Repurchase Mandate 18

Notice of Annual General Meeting 21

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"2025 Final Dividend"	The proposed final dividend of RMB0.084 per Share for financial year 2025 subject to the approval by Shareholders at the Annual General Meeting
"Annual General Meeting"	the annual general meeting of the Company to be held at 14/F, Kunlun Center Office Building, No. 9, Fuyi Street, Fengtai District, Beijing, the People's Republic of China on Thursday, June 25, 2026 at 10 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the annual general meeting which is set out on pages 21 to 25 of this circular, or any adjournment thereof
"Articles of Association"	the articles of association of the Company currently in force
"Audit Committee"	the audit committee of the Company
"Board"	the board of Directors
"CCASS"	Central Clearing and Settlement System, a securities settlement system used within the Hong Kong Exchanges and Clearing Limited market system
"China" or "PRC"	the People's Republic of China, which for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company"	China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the main board of the Stock Exchange
"controlling shareholder"	has the meaning ascribed to it under the Listing Rules
"CR Healthcare"	China Resources Healthcare Group Limited, a company incorporated in Hong Kong with limited liability, and a subsidiary of China Resources (Holdings) Company Limited and a controlling shareholder of the Company
"Director(s)"	the director(s) of the Company
"Dividend Currency Election Form"	the form that a Shareholder must complete and return to the Company's branch share registrar in Hong Kong in the manner set out in this circular in order to elect to receive all (but not part) of the final dividend for the year ended December 31, 2025 in RMB

"Group"	the Company and its subsidiaries from time to time
"HKSCC"	Hong Kong Securities Clearing Company Limited
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Issuance Mandate"	as defined in paragraph 4 of the Letter from the Board on page 5 of this circular
"Latest Practicable Date"	May 27, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Nomination Committee"	the nomination committee of the Company
"Remuneration Committee"	the remuneration committee of the Company
"Repurchase Mandate"	as defined in paragraph 3 of the Letter from the Board on page 5 of this circular
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
"Share(s)"	ordinary share(s) of HK$0.00025 each in the capital of the Company
"Shareholder(s)"	holder(s) of Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subsidiary"	has the meaning ascribed to it under the Listing Rules
"Takeovers Code"	The Codes on Takeovers and Mergers and Share Buy-backs approved by the Securities and Futures Commission as amended from time to time
"treasury shares"	has the meaning ascribed to it under the Listing Rules
"%"	per cent

華潤醫療控股有限公司
China Resources Medical Holdings Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1515)

Executive Directors:
Mr. YU Hai *(Chairman of the Board)*
Mr. ZHANG Chuang *(Chief Executive Officer)*
Mr. WANG Yuexing
Mr. WU Xinchun *(Vice President)*

Non-executive Director:
Mr. FANG Xin

Independent Non-executive Directors:
Mr. WU Ting Yuk Anthony
Mr. FU Tingmei
Mr. ZHOU Peng
Ms. LO Wing Sze

Registered Office:
Ascentium (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
PO Box 10240
Grand Cayman, KY1-1002
Cayman Islands

Headquarters and Principal Place of Business in Chinese Mainland:
14/F, Kunlun Center Office Building
No. 9, Fuyi Street
Fengtai District, Beijing
the People's Republic of China

Headquarters and Principal Place of Business in Hong Kong:
Room 2603
26/F, China Resources Building
26 Harbour Road, Wanchai
Hong Kong

June 3, 2026

To the Shareholders

Dear Sir/Madam,

PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND ISSUE NEW SHARES AND PROPOSED PAYMENT OF FINAL DIVIDEND AND PROPOSED RE-APPOINTMENT OF INDEPENDENT AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the Annual General Meeting.

2. PROPOSED RE-ELECTION OF RETIRING DIRECTORS

In accordance with articles 86(3), 87(1) and 87(2) of the Articles of Association, Mr. YU Hai, Mr. ZHANG Chuang, Mr. WANG Yuexing, Mr. WU Xinchun, Mr. FANG Xin, Mr. ZHOU Peng and Ms. LO Wing Sze (the "**Retiring Directors**") shall retire by rotation at the Annual General Meeting. All of the Retiring Directors, being eligible, will offer themselves for re-election at the Annual General Meeting.

Nomination Procedures for Directors and Recommendations of the Nomination Committee

The Nomination Committee shall recommend to the Board on the appointment of Directors (including independent non-executive Directors) having regard to (i) the proposed candidates' qualification, background and experience; (ii) independence of candidates for independent non-executive Directors, which is assessed with reference to the factors set out in Rule 3.13 of the Listing Rules and any other factors deemed appropriate by the Nomination Committee or the Board; and (iii) the diversity of the Board in all aspects, including gender, age, cultural and educational background, professional experience, skills, knowledge and work experience.

The Nomination Committee has assessed the independence of each of the independent non-executive Directors who shall retire and proposed to be re-elected based on the independence criteria set out in Rule 3.13 of the Listing Rules, and confirmed that all of them are independent. In addition, the Nomination Committee has assessed and are satisfied with the performance of each of the Retiring Directors for the year ended December 31, 2025.

In particular, the Nomination Committee is also of the view that the Directors who are proposed to be subject to re-election at the Annual General Meeting would bring to the Board their own perspective, skills and experience, as further described in their biographies in Appendix I to this circular. Based on the Board diversity policy adopted by the Company, the Nomination Committee considers that each of the Directors who will be subject to re-election (i.e. the Retiring Directors) can contribute to the diversity of the Board, in particular, with their strong and diversified educational background and professional experience in their expertise. Therefore, in response to the recommendation of the Nomination Committee, the Board recommended all Retiring Directors to be re-elected as Directors at the Annual General Meeting. As a good corporate governance practice, each of the abovementioned Retiring Directors has abstained from voting at the relevant Board meeting on the resolution to recommend each of their re-election by the Shareholders at the Annual General Meeting.

Details of the Retiring Directors are set out in Appendix I to this circular.

3. PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES

At the annual general meeting of the Company held on June 5, 2025, a general mandate was granted to the Directors to repurchase Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to repurchase Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of new general mandate to the Directors to repurchase Shares on the Stock Exchange of not exceeding 10% of the total number of issued Shares (excluding treasury shares, if any) as at the date of passing of the proposed ordinary resolution (i.e. a total of 129,667,651 Shares on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting) (the "**Repurchase Mandate**"). The Directors wish to state that they have no immediate plan to repurchase any Shares pursuant to the Repurchase Mandate.

An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Repurchase Mandate is set out in Appendix II to this circular.

4. PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE NEW SHARES

At the annual general meeting of the Company held on June 5, 2025, a general mandate was granted to the Directors to issue new Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to issue new Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of new general mandate to the Directors to allot, issue or otherwise deal with new Shares of not exceeding 20% of the total number of issued Shares (excluding treasury shares, if any) as at the date of passing of the proposed ordinary resolution (including any sale or transfer of treasury shares of the Company) (i.e. a total of 259,335,303 Shares on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting) (the "**Issuance Mandate**"). An ordinary resolution to extend the Issuance Mandate by adding the number of Shares repurchased by the Company pursuant to the Repurchase Mandate will also be proposed at the Annual General Meeting.

The Directors wish to state that they have no immediate plan to issue any new Shares pursuant to the Issuance Mandate.

5. PROPOSED PAYMENT OF FINAL DIVIDEND

Reference is made to the annual results announcement of the Company dated March 24, 2026 for the year ended December 31, 2025 (the "**Annual Results Announcement**") and the annual report of the Company for the year ended December 31, 2025 published on April 23, 2026 (the "**Annual Report**") in relation to (among others) the declaration of the 2025 Final Dividend.

At the Board meeting held on March 24, 2026, the Directors recommended a final dividend of RMB0.084 per Share for the year ended December 31, 2025 (final dividend for the financial year ended December 31, 2024: RMB0.082 per Share).

As the Annual General Meeting will be held at 14/F, Kunlun Center Office Building, No. 9, Fuyi Street, Fengtai District, Beijing, the People's Republic of China on Thursday, June 25, 2026 at 10:00 a.m., the original book closure dates for the purpose of determining the entitlement to the 2025 Final Dividend (subject to Shareholders' approval at the Annual General Meeting) as set out in the Annual Results Announcement are revised as follows:

	Original	**Revised**
Latest time to lodge transfers in order to be entitled to the 2025 Final Dividend	4:30 p.m. on Tuesday, June 16, 2026	4:30 p.m. on Thursday, July 2, 2026
Closure dates of register of members (both days inclusive)	Wednesday, June 17, 2026 to Thursday, June 18, 2026	Friday, July 3, 2026 to Monday, July 6, 2026
Record date	Thursday, June 18, 2026	Monday, July 6, 2026
Latest time to lodge dividend currency election form	4:30 p.m. on Monday, July 13, 2026	4:30 p.m. on Monday, July 27, 2026
2025 Final Dividend payment date	Wednesday, July 22, 2026	Monday, August 10, 2026

During the revised periods of the closure of register of members, no share transfers will be registered. For registration, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong before the relevant latest time to lodge transfers. Save for the changes as stated above, all other information and contents as set out in the Annual Results Announcement and the Annual Report shall remain unchanged.

Subject to the approval by the Shareholders at the Annual General Meeting, the 2025 Final Dividend will be paid on Monday, August 10, 2026 to Shareholders whose names appear on the Company's register of members at the close of business on Monday, July 6, 2026, being the record date for determining Shareholders' entitlement to the 2025 Final Dividend. This represents a total distribution of the 2025 Final Dividend of approximately RMB109 million (on the basis that the number of shares in issue of the Company remains unchanged on the date of the Annual General Meeting).

The 2025 Final Dividend will be payable in cash to each Shareholder in HK$ at the average benchmark exchange rate of RMB to HK$ as published by the People's Bank of China during the five business days ending on Thursday, June 25, 2026 (inclusive), being the date of the annual general meeting, unless an election is made to receive the same in RMB. To make such election, Shareholders should complete the Dividend Currency Election Form, which is expected to be despatched to Shareholders in early July 2026 as soon as practicable after the record date of Monday, July 6, 2026 to determine Shareholders' entitlement to the 2025 Final Dividend, and return it to the Company's branch share registrar in Hong Kong, Computershare

Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, July 27, 2026. Shareholders who are minded to elect to receive all (but not part) of the 2025 Final Dividend in RMB by cheques should note that (i) they should ensure that they have an appropriate bank account to which the RMB cheques for dividend can be presented for payment; and (ii) there is no assurance that RMB cheques can be cleared without material handling charges or delay in Hong Kong or that RMB cheques will be honoured for payment upon presentation outside Hong Kong. The cheques are expected to be posted to the relevant Shareholders by ordinary post on Monday, August 10, 2026 at the Shareholders' own risk.

If no election is made by a Shareholder or no duly completed Dividend Currency Election Form in respect of that Shareholder is received by the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, by 4:30 p.m. on Monday, July 27, 2026, such Shareholder will automatically receive the 2025 Final Dividend in HK$.

All dividend payments in HK$ will be made in the usual way on Monday, August 10, 2026. If Shareholders wish to receive the 2025 Final Dividend in HK$ in the usual way, no additional action is required. Shareholders should seek professional advice from their own tax advisors regarding the possible tax implications of the proposed dividend payment.

6. PROPOSED RE-APPOINTMENT OF INDEPENDENT AUDITOR

With the recommendation of the Audit Committee, the Board also resolved to re-appoint KPMG ("**KPMG**") as the independent auditor of the Company to hold office until the next annual general meeting of the Company, subject to the approval of the Shareholders by way of an ordinary resolution at the Annual General Meeting.

The estimated audit fee as preliminarily agreed with and payable to KPMG for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year ending December 31, 2026 is expected to be in the range of approximately RMB5.3 million to RMB5.5 million.

The estimated audit fee has been determined after due consideration and arm's length negotiations between the Company and KPMG taking into account, among others, the latest business operations and nature of the Group, the expected scope of audit, the expected audit timetable, and the level of professional supports and resources required.

The Board considered that the estimated audit fee represents a fair and reasonable estimation after due consideration, and did not expect the final audit fee would substantially deviate from the aforementioned estimate, unless there is a material change in the basis or assumptions.

An ordinary resolution will be proposed at the Annual General Meeting to re-appoint KPMG as the independent auditor of the Company for the year ending December 31, 2026 and to authorize the Board to fix their remuneration.

7. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 21 to 25 of this circular.

Pursuant to the Listing Rules and the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under the Listing Rules.

A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.crmedical.hk). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority, if any, under which it is signed or a certified copy of power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the Annual General Meeting (i.e. not later than 10 a.m. on Tuesday, June 23, 2026 (Hong Kong time)) or any adjournment thereof. Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting should you so wish.

8. RECOMMENDATION

The Directors consider that the proposed re-election of the Retiring Directors, the proposed granting of the Repurchase Mandate and the Issuance Mandate, the proposed payment of 2025 Final Dividend and the proposed re-appointment of independent auditor are in the interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

9. RESPONSIBILITY STATEMENT

This circular, for which the Directors jointly and severally accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
For and on behalf of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

The following are details of the Directors who will retire and being eligible, offer themselves for re-election at the Annual General Meeting.

(1) Mr. YU Hai

Mr. YU Hai, aged 58, joined the Group in February 2023 as an executive Director and the chief executive officer of the Company (the "**Chief Executive Officer**"). He was appointed as the chairman of the Board and the chairman of the Nomination Committee in June 2025, and resigned as the Chief Executive Officer in November 2025. He is currently the chairman of CR Healthcare. Mr. YU served as the vice-chairman, the general manager and the senior vice general manager of CR Healthcare from January 2020 to June 2025 and as the chairman of Liaoning Healthcare Industry Group Co., Ltd. from July 2018 to January 2020. Mr. YU worked in Benxi Municipal Government, Liaoning Province from July 2008 to July 2018, and served as the deputy mayor of Benxi City etc. Prior to that, Mr. YU held various positions at government departments including the deputy director of the Social Development Division of the Department of Science & Technology of Liaoning Province, the deputy director of the High-tech Development and Industrialization Division of the Department of Science & Technology of Liaoning Province, the deputy director of the Bureau of Science and Technology of Nagchu District, the Tibet Autonomous Region, and the principal officer of the Industrial and Social Development Division, the Scientific and Technological Commission of Liaoning Province etc.. Mr. YU holds a doctor of science degree in pharmaceutical affairs management from the School of Pharmacy, Shenyang Pharmaceutical University.

Save as disclosed above, Mr. YU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. YU has re-entered into a service agreement with the Company for the term of three years, commencing from February 27, 2026 to February 26, 2029 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. YU shall not receive any director's fees from the Company, but he shall be entitled to receive remuneration and pre-tax basic monthly salary of RMB73,800 from the Company by taking up other positions, duties and responsibilities. The emolument of Mr. YU shall be determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group. Mr. YU shall also be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). For the year ended December 31, 2025, Mr. YU has received remuneration and allowance in the total amount of RMB1,422,000 and performance bonus of RMB1,085,000.

As at the Latest Practicable Date, Mr. YU does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. YU involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. YU that need to be brought to the attention of the Shareholders and the Stock Exchange.

(2) Mr. ZHANG Chuang

Mr. ZHANG Chuang, aged 48, was appointed as an executive Director and the Chief Executive Officer in November 2025. He currently serves as the general manager and a director of CR Healthcare. He successively served as the assistant general manager and the deputy general manager of CR Healthcare from September 2014 to June 2025; and successively served as the senior manager to the board office and the deputy director of China Resources (Holdings) Company Limited from May 2010 to September 2014. He was the office manager and the secretary to the chief executive officer of China Worldbest Group Co., Ltd.*, the office manager of Sanjiu Enterprise Group*, the manager of human resources and administration department, the secretary to the president, and the assistant general manager of China Resources Pharmaceutical Group Limited from April 2007 to May 2010. He also successively served as the deputy director of the operations department, the deputy director and director of the business department of Shenzhen China Resources Petrochemical Investment and Development Co., Ltd.* from January 2003 to April 2007. Mr. ZHANG holds a bachelor's degree in engineering from the Beijing Institute of Petrochemical Technology and has the title of intermediate economist.

Save as disclosed above, Mr. ZHANG (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. ZHANG has entered into a service agreement with the Company for the term of three years, commencing from November 7, 2025 to November 6, 2028 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. ZHANG shall not receive any director's fees from the Company, but he shall be entitled to receive remuneration and pre-tax basic monthly salary of RMB69,100 from the Company by taking up other positions, duties and responsibilities. The emolument of Mr. ZHANG shall be determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group. Mr. ZHANG shall also be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration

Committee (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). For the year ended December 31, 2025, Mr. ZHANG has received remuneration and allowance in the total amount of RMB170,000 as an executive Director since November 7, 2025.

As at the Latest Practicable Date, Mr. ZHANG is interested in 260,000 shares of China Resources Building Materials Technology Holdings Limited (an associated corporation of the Company, the shares of which are listed on the Stock Exchange, stock code: 1313). Saved as disclosed above, Mr. ZHANG does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. ZHANG involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. ZHANG that need to be brought to the attention of the Shareholders and the Stock Exchange.

(3) Mr. WANG Yuexing

Mr. WANG Yuexing, aged 55, was appointed as an executive Director in February 2026. He is currently a director of CR Healthcare. Mr. WANG served as the deputy general manager of China Resources Life Science Group Company Limited* (華潤生命科學集團有限公司) from August 2019 to November 2022; the vice chairman of the board of directors of China Resources Life Science Industry Development Company Limited* (華潤生命科學產業發展有限公司) from June 2018 to August 2019; the deputy general manager of Beijing General Aviation Co., Ltd.* (北京通用航空有限公司) from February 2014 to June 2018; and successively served as the vice manager of the capital operation department, the secretary of the board, the director of the office of the board, the general legal counsel and the director in strategic planning etc. of Beijing Pharmaceutical Group Co., Ltd. from September 2003 to February 2014. Mr. WANG holds a doctoral degree in economics from the school of economics of Renmin University of China and has the title of senior economist.

Save as disclosed above, Mr. WANG (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. WANG has entered into a service agreement with the Company for the term of three years, commencing from February 27, 2026 to February 26, 2029 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. WANG shall not receive any director's fees from the Company, but he shall be entitled to receive pre-tax basic monthly salary of RMB62,800 in remuneration from the Company based on his other positions, duties and responsibilities in the Group. The emoluments of Mr. WANG shall be determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group. Mr. WANG shall be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee which shall be determined with reference to the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director.

As at the Latest Practicable Date, Mr. WANG does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. WANG involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. WANG that need to be brought to the attention of the Shareholders and the Stock Exchange.

(4) Mr. WU Xinchun

Mr. WU Xinchun, aged 55, has been serving as the vice president of the Company since December 2018 and was appointed as an executive Director in November 2025. He is currently the deputy general manager of CR Healthcare and the directors of certain subsidiaries of the Company. Mr. WU served as the assistant to the general manager of Wuhan Iron and Steel Group Co., Ltd.* from December 2017 to December 2018; the executive director and general manager of Wugang Modern City Services Group Co., Ltd*, the chairman of China Resources Wuhan Iron and Steel Medical Management Co., Ltd.* from November 2015 to December 2018. He successively served as the deputy secretary-general of the China Iron and Steel Association, and positions including the director of the technical management division of the technical quality department, the director of the science and technology innovation department and the intellectual property management department, the director of the information center, the general manager of the information and innovation department of Wuhan Iron and Steel Group Corporation* from September 2001 to November 2015. Mr. WU holds a doctoral degree in engineering from Wuhan University of Technology and holds the title of senior engineer at professor level.

Save as disclosed above, Mr. WU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. WU has entered into a service agreement with the Company for the term of three years, commencing from November 7, 2025 to November 6, 2028 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. WU shall not receive any director's fees from the Company, but he shall be entitled to receive remuneration and pre-tax basic monthly salary of RMB59,500 from the Company by taking up other positions, duties and responsibilities. The emolument of Mr. WU shall be determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group. Mr. WU shall also be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). For the year ended December 31, 2025, Mr. WU has received remuneration and allowance in the total amount of RMB165,000 as an executive Director since November 7, 2025.

As at the Latest Practicable Date, Mr. WU is interested in 140,230 shares of the Company. Saved as disclosed above, Mr. WU does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. WU involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. WU that need to be brought to the attention of the Shareholders and the Stock Exchange.

(5) Mr. FANG Xin

Mr. FANG Xin, aged 50, was appointed as a non-executive Director in March 2026. He currently serves as a director of CR Healthcare. He also currently serves as an external director of the business units of China Resources (Holdings) Company Limited. Mr. FANG has served as a non-executive director of China Resources Vanguard (Holding) Company Limited since February 2025, and a non-executive director of China Resources Gas Group Limited (the shares of which are listed on the main board of the Stock Exchange, stock code: 1193) since January 2025. Mr. FANG joined China Resources Group in August 1996, has successively served in various positions in the China Resources Group. He served as a director of China Resources Chemical Innovative Materials Co., LTD. ("**CR Materials**", the shares of which are

listed on the Shenzhen Stock Exchange, stock code: 301090) from January 2020 to December 2024, the period in which he concurrently served as the assistant general manager from January 2020 to August 2021; the vice general manager from August 2021 to January 2022; and the general manager from January 2022 to December 2024 in CR Materials respectively. Mr. FANG also served as the director of the procurement department from January 2008 to August 2018 and as the assistant general manager from November 2012 to January 2020, respectively, in China Resources Chemicals Holdings Limited (now known as China Resources Chemical Innovative Materials Holdings Limited). Mr. FANG holds a bachelor's degree in engineering from Beijing Institute of Technology.

Save as disclosed above, Mr. FANG (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. FANG has entered into a service agreement with the Company for the term of three years, commencing from March 11, 2026 to March 10, 2029 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. FANG will not be entitled to any form of remuneration from the Group in respect of his appointment as a non-executive Director.

As at the Latest Practicable Date, Mr. FANG is interested in (i) approximately 101,265 shares of CR Materials (being indirect interest through a strategic placement collective asset management scheme), an associated corporation of the Company; and (ii) 20,000 shares of China Resources Power Holdings Company Limited, an associated corporation of the Company (the shares of which are listed on the main board of the Stock Exchange, stock code: 836). Saved as disclosed above, Mr. FANG does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. FANG involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. FANG that need to be brought to the attention of the Shareholders and the Stock Exchange.

(6) Mr. ZHOU Peng

Mr. ZHOU Peng, aged 49, was appointed as an independent non-executive Director and a member of the Audit Committee in September 2023. Mr. ZHOU served as an executive director of HKE Holdings Limited (which is listed on the main board of the Stock Exchange, stock code: 1726) from August 2024 to January 2026. He is the founder of Deep Blue Ridge Capital ("**DBR Capital**"). DBR Capital is a multi-strategy investment firm based in Hong Kong. Mr. ZHOU has 20 years of experience in global mergers and acquisitions and capital markets. Before founding DBR Capital, Mr. ZHOU worked in Deutsche Bank (Hong Kong) and Credit Suisse (New York), and cooperated with the world's top institutional and corporate clients to complete a number of cross-industry and cross-product transactions; and Mr. ZHOU's career began in Bank of China. Mr. ZHOU holds a master's degree in business administration from Columbia University in New York.

Save as disclosed above, Mr. ZHOU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Mr. ZHOU has entered into a letter of appointment with the Company for a term of three years from September 14, 2023 to September 13, 2026 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. He is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Mr. ZHOU is entitled to a director's fee of HK$300,000 per annum and the discretionary bonus at the sole and absolute discretion of the Board and the Remuneration Committee (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). The emolument of Mr. ZHOU was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

As at the Latest Practicable Date, Mr. ZHOU does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Mr. ZHOU involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. ZHOU that need to be brought to the attention of the Shareholders and the Stock Exchange.

(7) Ms. LO Wing Sze

Ms. LO Wing Sze, BBS, JP, aged 54, was appointed as an independent non-executive Director in June 2025. Ms. LO is the financial director of Million Group, and has 27 years of experience in corporate governance and tourism management.

Ms. LO is a member of the Election Committee 2021 (The Fourth Sector) of the Hong Kong Special Administrative Region ("**HKSAR**") and was a member of the Election Committee for the Fifth Government of the HKSAR (Tourism Subsector). She is an All-China Women's Federation HKSAR delegate.

Ms. LO is a member of the Chief Executive's Policy Unit Expert Group, the Lotteries Fund Advisory Committee, the Immigration Department Users' Committee, the Correctional Services Children's Education Trust Investment Advisory Board and the District Fight Crime Committee (Wan Chai District). She is also an Honorary Court Member of the Lingnan University. Ms. LO is a founding member of Hong Kong Red Cross EmpowerHer Network and a member of the Hong Kong Society of Rehabilitation Fundraising and Social Enterprise Committee.

Ms. LO is currently an independent non-executive director of China Resources Mixc Lifestyle Services Limited (stock code: 1209), New World Development Company Limited (stock code: 17), Goldlion Holdings Limited (stock code: 533) and Lee & Man Paper Manufacturing Limited (stock code: 2314), all being companies listed on the Stock Exchange. She served as an independent non-executive director of Finsoft Financial Investment Holdings Limited (a company listed on the Stock Exchange, stock code: 8018) from August 2020 to July 2023, and an independent non-executive director of Virtual Mind Holding Company Limited (a company listed on the Stock Exchange, stock code: 1520) from January 2021 to June 2025.

Ms. LO holds a bachelor of economics degree from the University of Sydney and a master of commerce in finance Degree from the University of New South Wales in Australia. She is a member of the Hong Kong Institute of Certified Public Accountants and a fellow member of CPA Australia.

Save as disclosed above, Ms. LO (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Ms. LO has entered into a letter of appointment with the Company for a term of three years from June 19, 2025 to June 18, 2028 and subject to termination before expiry by either party giving not less than one month's notice in writing to the other. She is subject to retirement by rotation and re-election at the Annual General Meeting in accordance with the Articles of Association. Ms. LO is entitled to a director's fee of HK$300,000 per annum which was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

As at the Latest Practicable Date, Ms. LO does not have any interests in the Shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO.

Save for the information disclosed above, there is no information which is discloseable nor is Ms. LO involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Ms. LO that need to be brought to the attention of the Shareholders and the Stock Exchange.

* *For identification purpose only*

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the Annual General Meeting in relation to the granting of the Repurchase Mandate.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital (excluding treasury shares, if any) of the Company comprised 1,296,676,516 Shares. As at the Latest Practicable Date, the Company did not hold any treasury shares.

Subject to the passing of the ordinary resolution set out in item 6 of the notice of the Annual General Meeting in respect of the granting of the Repurchase Mandate and on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting, i.e. being 1,296,676,516 Shares, the Directors would be authorized under the Repurchase Mandate to repurchase, during the period in which the Repurchase Mandate remains in force, a total of 129,667,651 Shares, representing 10% of the total number of Shares in issue (excluding treasury shares, if any) as at the date of the Annual General Meeting.

2. REASONS FOR SHARE REPURCHASE

The Directors believe that the granting of the Repurchase Mandate is in the interests of the Company and the Shareholders.

Shares repurchase may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders. On the other hand, Shares repurchased by the Company and held as treasury shares may provide more flexibility to the Board to resell the treasury shares on the market prices to raise additional funds for the Company, or transfer or use for share grants under share schemes that comply with Chapter 17 of the Listing Rules and for other purposes permitted under the Listing Rules, the Articles and the applicable laws of the Cayman Islands.

3. FUNDING OF SHARE REPURCHASE

In repurchasing Shares, the Company may only apply funds legally available for such purpose in accordance with its Articles of Association, the laws of Cayman Islands and/or any other applicable laws, as the case may be.

4. IMPACT OF SHARE REPURCHASE

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited accounts contained in the annual report of the Company for the year ended December 31, 2025) in the event that the Repurchase Mandate was to be carried out in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such

extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which, in the opinion of the Directors, are from time to time appropriate for the Company.

The Company may cancel such repurchased Shares or hold them as treasury shares, subject to market conditions and the Group's capital management needs at the relevant time of the repurchases.

For any treasury shares deposited with CCASS pending resale on the Stock Exchange, the Company shall (i) procure its broker not to give any instructions to HKSCC to vote at general meetings of the Company for the treasury shares deposited with CCASS; and (ii) in the case of dividends or distributions, withdraw the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the record date for the dividends or distributions, or take any other measures to ensure that it will not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those shares were registered in its own name as treasury shares.

5. MARKET PRICES OF SHARES

The highest and lowest prices per Share at which Shares have traded on the Stock Exchange during each of the previous 12 months up to and including the Latest Practicable Date were as follows:

Month	**Highest**	**Lowest**
	HK$	*HK$*
May 2025	4.17	3.60
June 2025	4.26	3.84
July 2025	4.70	4.05
August 2025	4.56	3.59
September 2025	3.72	3.41
October 2025	3.53	3.38
November 2025	3.45	3.23
December 2025	3.34	3.18
January 2026	3.47	3.17
February 2026	3.23	3.03
March 2026	3.12	2.62
April 2026	2.93	2.70
May 2026 (up to the Latest Practicable Date)	2.89	2.48

6. GENERAL

The Directors will exercise the powers of the Company to make repurchases pursuant to the Repurchase Mandate and in accordance with the Listing Rules and the applicable laws of the Cayman Islands. Neither this explanatory statement nor the Repurchase Mandate has any unusual features.

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, their close associates (as defined in the Listing Rules), has any present intention to sell any Shares to the Company or its subsidiaries under the Repurchase Mandate if such is approved by the Shareholders.

No core connected persons (as defined in the Listing Rules) of the Company have notified the Company that they have a present intention to sell Shares to the Company or its subsidiaries, or have undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

7. TAKEOVERS CODE

If as a result of a repurchase of Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (as defined in the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

To the best knowledge of the Company, as at the Latest Practicable Date, China Resources Company Limited, the substantial shareholder of the Company (as defined in the Listing Rules), was interested in 474,319,516 Shares, representing approximately 36.58% of the total issued share capital of the Company. In the event that the Directors exercise the proposed Repurchase Mandate in full, the aggregate shareholding interest of China Resources Company Limited would be increased to approximately 40.64% of the issued share capital of the Company.

The Directors consider that such increase in shareholding may give rise to an obligation for China Resources Company Limited to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors do not have any present intention to exercise the proposed Repurchase Mandate to such an extent as would give rise to such an obligation.

In addition, the Directors do not have any intention to exercise the proposed Repurchase Mandate to the effect that it will result in the public float to fall below the percentage as required under the Listing Rules or such other minimum percentage agreed by the Stock Exchange from time to time.

8. REPURCHASE OF SHARES MADE BY THE COMPANY

During the 6 months immediately preceding the Latest Practicable Date, the Company has not repurchased any of the Shares (whether on the Stock Exchange or otherwise).

華潤醫療控股有限公司
China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

NOTICE IS HEREBY GIVEN THAT an annual general meeting (the "**Annual General Meeting**") of China Resources Medical Holdings Company Limited (華潤醫療控股有限公司) (the "**Company**") will be held at 10 a.m. on Thursday, June 25, 2026 at 14/F, Kunlun Center Office Building, No. 9, Fuyi Street, Fengtai District, Beijing, the People's Republic of China for the following purposes:

ORDINARY RESOLUTIONS

1. To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the "**Directors**") and auditors of the Company for the year ended December 31, 2025;

2. To declare a final dividend of RMB0.084 per ordinary share of the Company for the year ended December 31, 2025;

3. (1) To re-elect Mr. YU Hai as an executive Director;

   (2) To re-elect Mr. ZHANG Chuang as an executive Director;

   (3) To re-elect Mr. WANG Yuexing as an executive Director;

   (4) To re-elect Mr. WU Xinchun as an executive Director;

   (5) To re-elect Mr. FANG Xin as a non-executive Director;

   (6) To re-elect Mr. ZHOU Peng as an independent non-executive Director;

   (7) To re-elect Ms. LO Wing Sze as an independent non-executive Director;

4. To authorize the board of Directors (the "**Board**") to fix the respective Directors' remuneration;

5. To re-appoint KPMG as the independent auditor of the Company for the year ending December 31, 2026 and to authorize the Board to fix their remuneration;

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the Directors to exercise during the Relevant Period (as defined below) all the powers of the Company to repurchase its shares (and the Company may hold the shares so repurchased in treasury) in accordance with all applicable laws, rules and regulations;

(b) the total number of shares of the Company to be repurchased pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total number of issued shares (excluding treasury shares, if any) of the Company as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be repurchased under the mandate in paragraph (a) above as a percentage of the total number of issued shares at the date immediately before and after such consolidation or subdivision shall be the same; and

(c) for the purposes of this resolution, "**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.";

7. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (c) below, a general mandate be and is hereby generally and unconditionally given to the Directors during the Relevant Period (as defined below) to allot, issue and deal with additional shares in the capital of the Company, including any sale or transfer the treasury shares of the Company, and to make or grant offers, agreements and options which might require the exercise of such powers;

(b) the mandate in paragraph (a) above shall authorize the Directors to make or grant offers, agreements and options during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the total number of shares allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under a share option scheme of the Company;

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares of the Company in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company; or

(iv) the exercise of rights of subscription or conversion under the term, of any warrants of the Company or any securities of the Company which carry rights to subscribe for or are convertible into shares of the Company,

shall not exceed 20% of the total number of issued shares (excluding treasury shares, if any) of the Company as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares of the Company is conducted, the maximum number of shares of the Company that may be issued under the mandate in paragraph (a) above as a percentage of the total number of issued shares of the Company at the date immediately before and after such consolidation or subdivision shall be the same; and

(d) for the purposes of this resolution, "**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

"**Rights Issue**" means an offer of shares or offer or issue of warrants, options or other securities giving rights to subscribe for shares open for a period fixed by the Directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange).''; and

8. As special business, to consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT** conditional upon the passing of the resolutions set out in items 6 and 7 of the notice convening this meeting (the "**Notice**"), the general mandate referred to in the resolution set out in item 7 of the Notice be and is hereby extended by the addition to the total number of shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the Directors pursuant to such general mandate of the number of shares repurchased by the Company pursuant to the mandate referred to in resolution set out in item 6 of the Notice, provided that such amount shall not exceed 10% of the total number of issued shares (excluding treasury shares, if any) of the Company as at the date of passing of this resolution."

By order of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, June 3, 2026

Notes:

1. Any member of the Company entitled to attend and vote at the above meeting is entitled to appoint another person as his proxy to attend and vote instead of him. A member who is the holder of two or more shares may appoint more than one proxy to represent him and vote on his behalf at the above meeting. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.

2. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the holding of the meeting (i.e. not later than 10 a.m. on Tuesday, June 23, 2026 (Hong Kong time)) or any adjournment thereof. Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

3. For determining the entitlement to attend and vote at the above meeting, the register of members of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both dates inclusive, during which period no transfer of shares will be registered. Shareholders whose names appear on the register of members of the Company on Thursday, June 25, 2026 i.e. the record date, are entitled to attend and vote at the Annual General Meeting. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than Hong Kong time 4:30 p.m. on Thursday, June 18, 2026.

4. Reference is made to the section headed "5. Proposed Payment of Final Dividend" in the circular of the Company dated June 3, 2026 in relation to, among others, revision of the dividend payment date and the relevant book closure period. For determining the entitlement to the proposed final dividend (subject to approval by the shareholders at the Annual General Meeting), the register of members of the Company will be closed from Friday, July 3, 2026 to Monday, July 6, 2026, both dates inclusive, during which period no transfer of shares will be registered. Shareholders whose names appear on the register of members of the Company on Monday, July 6, 2026 are entitled to the proposed final dividend, being the record date for determining Shareholders' entitlement to the 2025 Final Dividend. In order to qualify for the proposed final dividend, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than Hong Kong time 4:30 p.m. on Thursday, July 2, 2026.

5. All the resolutions set out in this notice shall be decided by poll.